Showing 1231-1240 of 21420 results for "".
- Icon Skincare Launches Prestige Brand Focused on Simplicity, Confidence, and Ritualhttps://reachmd.com/news/icon-skincare-launches-prestige-brand-focused-on-simplicity-confidence-and-ritual/2487304/Innovative Skincare, the company behind the global cosmeceutical brand iS Clinical, has announced the launch of Icon Skincare, a new prestige skincare line designed to simplify routines while emphasizing skin health, confidence, and daily ritual. Founded by Bryan Johns and Alec Call, Icon
- Lifestyle Intervention Improves Natural Conception but Not Live Birthshttps://reachmd.com/news/lifestyle-intervention-improves-natural-conception-but-not-live-births/2487308/A structured lifestyle intervention helped women with obesity and infertility achieve more natural pregnancies, but it did not significantly improve live-birth rates compared with usual fertility care, according to
- Four IBS Diet Strategies Show Distinct Profiles In Reviewhttps://reachmd.com/news/four-ibs-diet-strategies-show-distinct-profiles-in-review/2487297/Key Takeaways Low FODMAP interventions showed relatively consistent short-term response, but pooled analysis did not show a significant advantage over other dietary approaches. Mediterranean-based interventions appeared promising at longer follow-up in
- Ketamine Versus Etomidate for Tracheal Intubation in Critically Ill Adultshttps://reachmd.com/news/ketamine-versus-etomidate-for-tracheal-intubation-in-critically-ill-adults/2487293/Key Takeaways Ketamine was not associated with a significant reduction in day-28 in-hospital death versus etomidate. Cardiovascular collapse was reported more often with ketamine during intubation. Prespecified safety outcomes were similar in
- Tirzepatide vs Intensified Conventional Care at 2 Years in Early T2Dhttps://reachmd.com/news/tirzepatide-vs-intensified-conventional-care-at-2-years-in-early-t2d/2487296/Key Takeaways Tirzepatide was associated with greater reductions in HbA1c, weight, and waist circumference than intensified conventional care over 2 years. More participants achieved normoglycemia with tirzepatide than with intensified conventional car
- Study: JAK Inhibitor–Excimer Laser Combination Improves Repigmentation in Pediatric Vitiligohttps://reachmd.com/news/jak-inhibitorexcimer-laser-combination-improves-repigmentation-in-pediatric-vitiligo-trial/2487301/Children with progressive vitiligo treated with an oral Janus kinase (JAK) inhibitor combined with 308-nm excimer laser therapy experienced significantly greater repigmentation than those treated with topical tacrolimus and excimer laser therapy, according to
- Strategies That Improved Childhood Routine Immunization Coveragehttps://reachmd.com/news/strategies-that-improved-childhood-routine-immunization-coverage/2487271/Key Takeaways Across 28 identified strategies, consistent gains were reported for cash transfers, home-based identification and outreach, and informational vaccination sessions. Cash transfers showed small gains, home-based outreach showed small-to-mod
- Upadacitinib Plus Vedolizumab Induction in Moderate-To-Severe UChttps://reachmd.com/news/upadacitinib-plus-vedolizumab-induction-in-moderate-to-severe-uc/2487220/Key Takeaways Endoscopic remission was observed more often with combination induction than with vedolizumab alone at the week-8 assessment. Combination therapy also showed higher clinical remission and histologic-endoscopic mucosal improvement at week
- Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis: Phase 3 Datahttps://reachmd.com/news/inhaled-treprostinil-in-idiopathic-pulmonary-fibrosis-phase-3-data/2487213/Key Takeaways Median forced vital capacity decline at week 52 was smaller with treprostinil than with placebo. Clinical worsening occurred in 31.8% versus 44.5%, with a hazard ratio of 0.67, and no significant difference was seen in time to IPF exacerb
- LNG IUS Outperformed Hysteroscopic Niche Resection At 3 Yearshttps://reachmd.com/news/lng-ius-outperformed-hysteroscopic-niche-resection-at-3-years/2487221/Key Takeaways Women assigned the levonorgestrel intrauterine system were more likely to meet the primary spotting reduction endpoint at 36 months. Improvement with the device continued through 36 months, while the hysteroscopic group improved through 2